Skip to main content

Expert Insights

Blog
04/24/2025
Molecular profiling is revolutionizing pediatric low-grade glioma (pLGG) management, driving precision-targeted therapies and reshaping diagnostic, treatment, and monitoring paradigms.
Molecular profiling is revolutionizing pediatric low-grade glioma (pLGG) management, driving precision-targeted therapies and reshaping diagnostic, treatment, and monitoring paradigms.
Molecular profiling is...
04/24/2025
Oncology
Blog
04/24/2025
With FDA-approved BRAF, MEK, and pan-RAF inhibitors transforming pediatric low-grade glioma (pLGG) care, learn how molecular targeting of MAPK pathway alterations is redefining frontline treatment strategies and outcomes.
With FDA-approved BRAF, MEK, and pan-RAF inhibitors transforming pediatric low-grade glioma (pLGG) care, learn how molecular targeting of MAPK pathway alterations is redefining frontline treatment strategies and outcomes.
With FDA-approved BRAF, MEK, and...
04/24/2025
Oncology
Blog
04/24/2025
With nearly all pediatric low-grade glioma (pLGG) tumors driven by MAPK pathway activation, targeted therapies are redefining treatment by tailoring approaches to the tumor’s specific genetic signature.
With nearly all pediatric low-grade glioma (pLGG) tumors driven by MAPK pathway activation, targeted therapies are redefining treatment by tailoring approaches to the tumor’s specific genetic signature.
With nearly all pediatric...
04/24/2025
Oncology
Eman Toraih, MD, PhD, DBio
Videos
04/23/2025
Eman Toraih, MD, PhD, DBio, discusses the use of radiofrequency ablation for patients with primary papillary thyroid carcinoma.
Eman Toraih, MD, PhD, DBio, discusses the use of radiofrequency ablation for patients with primary papillary thyroid carcinoma.
Eman Toraih, MD, PhD, DBio,...
04/23/2025
Oncology
Joan Garrett, PhD, University of Cincinnati
Videos
04/17/2025
Joan Garrett, PhD, discusses the role of HER3 receptor tyrosine kinase and NRG1 in oncology.
Joan Garrett, PhD, discusses the role of HER3 receptor tyrosine kinase and NRG1 in oncology.
Joan Garrett, PhD, discusses the...
04/17/2025
Oncology
Ruth He, MD
Videos
04/15/2025
Aiwu Ruth He, MD, PhD
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses...
04/15/2025
Oncology
Videos
04/14/2025
Namrata Vijayvergia, MD, FACP; Jason A. Zell, DO, MPH
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) surveillance setting.
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) surveillance setting.
Drs Zell and Vijayvergia debate...
04/14/2025
Oncology
Videos
04/14/2025
Namrata Vijayvergia, MD, FACP; Jason A. Zell, DO, MPH
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) adjuvant setting.
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) adjuvant setting.
Drs Zell and Vijayvergia debate...
04/14/2025
Oncology
Videos
04/14/2025
Namrata Vijayvergia, MD, FACP; Jason A. Zell, DO, MPH
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) neoadjuvant setting.
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) neoadjuvant setting.
Drs Zell and Vijayvergia debate...
04/14/2025
Oncology
Videos
04/14/2025
Yelena Y. Janjigian, MD
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Given ongoing advancements in...
04/14/2025
Oncology